{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04456959",
      "OrgStudyIdInfo": {
        "OrgStudyId": "X9001222"
      },
      "Organization": {
        "OrgFullName": "Pfizer",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "InO - A Retrospective Study of UK Patients With Leukaemia",
      "OfficialTitle": "A Retrospective Chart Review of UK Patients With Relapsed/Refractory Acute Lymphoblastic Leukaemia Treated With Inotuzumab Ozogamicin, a Real World Research Study",
      "Acronym": "InO"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2021",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 6, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 27, 2021",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 27, 2021",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "June 8, 2020",
      "StudyFirstSubmitQCDate": "June 29, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 7, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 8, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 9, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Pfizer",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "PatientRegistry": "No",
      "DesignInfo": {
        "DesignObservationalModelList": {
          "DesignObservationalModel": [
            "Cohort"
          ]
        },
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Retrospective"
          ]
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "28",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Adult R/R ALL patients who have received InO",
            "ArmGroupDescription": "Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Inotuzumab Ozogamicin"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Inotuzumab Ozogamicin",
            "InterventionDescription": "Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Adult R/R ALL patients who have received InO"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "CMC-544"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Clinical characteristics",
            "PrimaryOutcomeDescription": "To describe patient demographic and clinical characteristics at initiation of Inotuzumab Ozogamicin",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Duration of treatment with InO",
            "SecondaryOutcomeDescription": "Description of the inotuzumab ozogamicin treatment pathway",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Number of cycles of InO",
            "SecondaryOutcomeDescription": "Description of the inotuzumab ozogamicin treatment pathway",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Interrupted cycles of InO, including reasons (liver toxicity TRAEs, other AEs, tolerance, treatment failure, and course complete).",
            "SecondaryOutcomeDescription": "Description of the inotuzumab ozogamicin treatment pathway",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Doses of InO prescribed",
            "SecondaryOutcomeDescription": "Description of the inotuzumab ozogamicin treatment pathway",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Modification of doses of InO, including reasons (liver toxicity TRAEs, other AEs, tolerance, treatment failure, and course complete).",
            "SecondaryOutcomeDescription": "Description of the inotuzumab ozogamicin treatment pathway",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Azole antifungal therapy concomitant to InO treatment",
            "SecondaryOutcomeDescription": "Description of the inotuzumab ozogamicin treatment pathway",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "CR, CRi and CR/CRi response rates by the end of InO treatment, overall and according to the number of salvage therapies in the pre-index observation period (0, 1, ≥2);",
            "SecondaryOutcomeDescription": "To summarise CR/CRi rates following treatment with inotuzumab ozogamicin, overall and stratified according to the number of salvage therapies (0, 1, ≥2) received prior to inotuzumab ozogamicin initiation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Median time to CR/CRi (95% CI)",
            "SecondaryOutcomeDescription": "To summarise median time to CR/CRi following treatment with inotuzumab ozogamicin",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Number and proportion of patients achieving MRD negativity overall and by the number of completed cycles of InO (after 1, 2, ≥3 cycles of InO) in patients evaluated by flow-cytometry/ molecular assessment / both.",
            "SecondaryOutcomeDescription": "To summarise MRD negativity rates following initiation of inotuzumab ozogamicin, and describe the number of cycles of inotuzumab ozogamicin needed to attain MRD negativity.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "The number and proportion of patients surviving at 3, 6 and 12 months after InO initiation",
            "SecondaryOutcomeDescription": "To describe overall survival, and cause of death; in all patients and in patient with or without follow-up hematopoietic stem-cell transplantation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Cause of death",
            "SecondaryOutcomeDescription": "To describe overall survival, and cause of death; in all patients and in patient with or without follow-up hematopoietic stem-cell transplantation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Median OS (95% CI)",
            "SecondaryOutcomeDescription": "To describe overall survival, and cause of death; in all patients and in patient with or without follow-up hematopoietic stem-cell transplantation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "The number and proportion of patients who are relapse-free at 3, 6 and 12 months after InO initiation; Median RFS (95% CI) In patients undergoing follow-up HSCT; Median NRM (95% CI) from the date of follow-up HSCT",
            "SecondaryOutcomeDescription": "To describe relapse-free-survival; in all patients and in patient with or without follow-up hematopoietic stem-cell transplantation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Median RFS (95% CI)",
            "SecondaryOutcomeDescription": "To describe relapse-free-survival; in all patients and in patient with or without follow-up hematopoietic stem-cell transplantation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "In patients undergoing follow-up HSCT; Median NRM (95% CI) from the date of follow-up HSCT",
            "SecondaryOutcomeDescription": "Describe non-relapse mortality in patients undergoing follow-up hematopoietic stemcell transplantation. Median NRM (95% CI) from the date of follow-up HSCT",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Document and report the number of patients who have received post-InO treatment including: new chemotherapy (blinatumomab, other), HSCT, CAR T cell therapy.",
            "SecondaryOutcomeDescription": "To describe the treatments for acute lymphoblastic leukaemia and responses to treatment post-inotuzumab ozogamicin, including hematopoietic stem cell transplantation, chemotherapy regimens and chimeric antigen receptor T-cell therapy.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "In those who received post InO treatment recorded response to treatment and survival",
            "SecondaryOutcomeDescription": "To describe the treatments for acute lymphoblastic leukaemia and responses to treatment post-inotuzumab ozogamicin, including hematopoietic stem cell transplantation, chemotherapy regimens and chimeric antigen receptor T-cell therapy.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of grade 3/4 treatment-related adverse events (lung/cardiac/kidney) following InO initiation in all patients",
            "SecondaryOutcomeDescription": "Record grade 3/4 treatment-related adverse events (lung/cardiac/kidney) in all patients following InO initiation",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of liver dysfunction following InO initiation in all patients",
            "SecondaryOutcomeDescription": "Record occurrence of liver safety events including VOD/SOS in all patient following InO initiation.",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with relapsed/refractory ALL.\nPatients who initiated InO between 1st of June 2016 and date of data collection.\nPatients who accessed InO treatment via NHS commissioning, via the CUP, or via private purchase.\nPatient aged ≥18 years old at initiation of InO treatment\n\nExclusion Criteria:\n\nPatients initiated on treatment with InO at a different hospital than the ones selected in this study.\nPatients with <3 months of follow-up since index date, unless death occurs <3 months from index date.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "Patients with relapsed/refractory Acute Lymphoblastic Leukemia who are aged 18 and over and initiated Inotuzumab Ozogamicin between 1st of June 2016 and date of data collection and received treatment via NHS commissioning, via the Compassionate Use Programme, or via private purchase.",
      "SamplingMethod": "Non-Probability Sample"
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Pfizer CT.gov Call Center",
            "OverallOfficialAffiliation": "Pfizer",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University Hospitals Bristol NHS Foundation Trust",
            "LocationCity": "Bristol",
            "LocationZip": "BS1 3NU",
            "LocationCountry": "United Kingdom"
          },
          {
            "LocationFacility": "University College London Hospital NHS Foundation Trust",
            "LocationCity": "London",
            "LocationZip": "NW1 2PG",
            "LocationCountry": "United Kingdom"
          },
          {
            "LocationFacility": "The Royal Marsden NHS Foundation Trust of Fulham Road",
            "LocationCity": "London",
            "LocationZip": "SW3 6JJ",
            "LocationCountry": "United Kingdom"
          },
          {
            "LocationFacility": "Taunton and Somerset NHS Foundation Trust of Musgrove Park Hospital",
            "LocationCity": "Taunton",
            "LocationZip": "TA1 5DA",
            "LocationCountry": "United Kingdom"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "To obtain contact information for a study center near you, click here.",
            "SeeAlsoLinkURL": "https://pmiform.com/clinical-trial-info-request?StudyID=X9001222"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No",
      "IPDSharingDescription": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007938",
            "ConditionMeshTerm": "Leukemia"
          },
          {
            "ConditionMeshId": "D000054198",
            "ConditionMeshTerm": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          },
          {
            "ConditionMeshId": "D000007945",
            "ConditionMeshTerm": "Leukemia, Lymphoid"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000008206",
            "ConditionAncestorTerm": "Lymphatic Diseases"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10097",
            "ConditionBrowseLeafName": "Leukemia",
            "ConditionBrowseLeafAsFound": "Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10103",
            "ConditionBrowseLeafName": "Leukemia, Lymphoid",
            "ConditionBrowseLeafAsFound": "Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M26738",
            "ConditionBrowseLeafName": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "ConditionBrowseLeafAsFound": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10355",
            "ConditionBrowseLeafName": "Lymphatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T175",
            "ConditionBrowseLeafName": "Acute Lymphoblastic Leukemia",
            "ConditionBrowseLeafAsFound": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3533",
            "ConditionBrowseLeafName": "Lymphoblastic Lymphoma",
            "ConditionBrowseLeafAsFound": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000080045",
            "InterventionMeshTerm": "Inotuzumab Ozogamicin"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000074322",
            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000000903",
            "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3377",
            "InterventionBrowseLeafName": "Antibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9336",
            "InterventionBrowseLeafName": "Immunoglobulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3382",
            "InterventionBrowseLeafName": "Antibodies, Monoclonal",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2103",
            "InterventionBrowseLeafName": "Inotuzumab Ozogamicin",
            "InterventionBrowseLeafAsFound": "7th",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M2118",
            "InterventionBrowseLeafName": "Calicheamicins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1346",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3374",
            "InterventionBrowseLeafName": "Anti-Bacterial Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3376",
            "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          }
        ]
      }
    }
  }
}